What question did this study set out to answer?

To evaluate the efficacy and safety of sustained-release bupropion, a nicotine patch, their combination, or placebo for long-term smoking cessation.

March 4, 1999New England Journal of MedicineOpen Access

A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation

View Full Paper

Ask AI

Bookmark

Authors

DJDouglas E. JorenbyUniversity of Wisconsin–Madison SLScott J. LeischowArizona State University MNMitchell NidesLos Angeles Clinical Trials

Discussion

Member takes

Overview

Randomized double-blind trial shows sustained-release bupropion alone or with a nicotine patch increases long-term abstinence in smokers, indicating combining therapies improves smoking cessation.

Key Points

To evaluate the efficacy and safety of sustained-release bupropion, a nicotine patch, their combination, or placebo for long-term smoking cessation.
Double-blind, placebo-controlled trial evaluating 893 adult smokers without depression, assigned to sustained-release bupropion (N=244), nicotine patch (N=244), bupropion plus patch (N=245), or placebo (N=160).
Intervention comprised 9 weeks of bupropion (150 mg daily for 3 days, then 150 mg twice daily) or placebo, plus 8 weeks of nicotine patches (tapered from 21 mg to 7 mg daily) or placebo, with quit target on day 8.
Abstinence rates at 12 months were 15.6% for placebo, 16.4% for nicotine patch alone, 30.3% for bupropion alone (P<0.001), and 35.5% for bupropion plus nicotine patch (P<0.001).
Mean weight gain at week 7 was 2.1 kg for placebo, 1.6 kg for nicotine patch, 1.7 kg for bupropion, and 1.1 kg for combined treatment (P<0.05 vs. bupropion and placebo).
Treatment was discontinued due to adverse events by 3.8% in placebo, 6.6% in patch, 11.9% in bupropion, and 11.4% in combined therapy groups, most commonly insomnia and headache.

Cite This Study

Jorenby et al. (1999) studied this question.

synapsesocial.com/papers/6a7127ee5671bbf00bc2d640 https://doi.org/10.1056/nejm199903043400903

View Full Paper

Ask AI

Bookmark

March 4, 1999New England Journal of MedicineOpen Access

A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation

View Full Paper

Ask AI

Bookmark

Authors

DJDouglas E. JorenbyUniversity of Wisconsin–Madison SLScott J. LeischowArizona State University MNMitchell NidesLos Angeles Clinical Trials

Discussion

Member takes

Overview

Randomized double-blind trial shows sustained-release bupropion alone or with a nicotine patch increases long-term abstinence in smokers, indicating combining therapies improves smoking cessation.

Key Points

To evaluate the efficacy and safety of sustained-release bupropion, a nicotine patch, their combination, or placebo for long-term smoking cessation.
Double-blind, placebo-controlled trial evaluating 893 adult smokers without depression, assigned to sustained-release bupropion (N=244), nicotine patch (N=244), bupropion plus patch (N=245), or placebo (N=160).
Intervention comprised 9 weeks of bupropion (150 mg daily for 3 days, then 150 mg twice daily) or placebo, plus 8 weeks of nicotine patches (tapered from 21 mg to 7 mg daily) or placebo, with quit target on day 8.
Abstinence rates at 12 months were 15.6% for placebo, 16.4% for nicotine patch alone, 30.3% for bupropion alone (P<0.001), and 35.5% for bupropion plus nicotine patch (P<0.001).
Mean weight gain at week 7 was 2.1 kg for placebo, 1.6 kg for nicotine patch, 1.7 kg for bupropion, and 1.1 kg for combined treatment (P<0.05 vs. bupropion and placebo).
Treatment was discontinued due to adverse events by 3.8% in placebo, 6.6% in patch, 11.9% in bupropion, and 11.4% in combined therapy groups, most commonly insomnia and headache.

Cite This Study

Jorenby et al. (1999) studied this question.

synapsesocial.com/papers/6a7127ee5671bbf00bc2d640 https://doi.org/10.1056/nejm199903043400903

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark